Forte Biosciences (FBRX) EBITDA (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly EBITDA of -$22.4 million for Q1 2026, down 39.17% year-over-year from -$36.9 million in Q1 2025, and up 8.68% quarter-over-quarter from -$24.6 million in Q4 2025.
Forte Biosciences (FBRX) EBITDA (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported EBITDA for 11 consecutive years, with -$22.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 39.17% year-over-year to -$22.4 million; the TTM figure through Mar 2026 stood at -$77.0 million (down 71.35% YoY), while the FY2025 annual figure was -$70.7 million, down 93.04% from the prior year.
- EBITDA improved to -$22.4 million in Q1 2026 per FBRX's latest filing, from -$24.6 million in the prior quarter.
- Across five years, EBITDA topped out at -$2.5 million in Q1 2022 and bottomed at -$24.6 million in Q4 2025.
- Historically, EBITDA has averaged -$10.4 million across 5 years, with a median of -$8.6 million in 2024.
- Annual changes were most pronounced in 2022 — EBITDA jumped 55.54% — and 2025, when it tumbled 234.25%.
- Forte Biosciences' EBITDA stood at -$4.9 million in 2022, then dropped by 29.2% to -$6.4 million in 2023, then slipped by 15.2% to -$7.4 million in 2024, then sank by 234.25% to -$24.6 million in 2025, then advanced by 8.68% to -$22.4 million in 2026.
- Business Quant data shows FBRX's EBITDA at -$22.4 million in Q1 2026, -$24.6 million in Q4 2025, and -$18.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | -24.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -24.60 Mn |
| Mar 31, 2026 | -22.44 Mn |
| Dec 31, 2025 | -24.57 Mn |
| Sep 30, 2025 | -18.38 Mn |
| Jun 30, 2025 | -11.58 Mn |
| Mar 31, 2025 | -16.12 Mn |
| Dec 31, 2024 | -7.35 Mn |
| Sep 30, 2024 | -8.63 Mn |
| Jun 30, 2024 | -12.82 Mn |
| Mar 31, 2024 | -7.80 Mn |
| Dec 31, 2023 | -6.38 Mn |
| Sep 30, 2023 | -10.22 Mn |
| Jun 30, 2023 | -9.03 Mn |
| Mar 31, 2023 | -6.86 Mn |
| Dec 31, 2022 | -4.94 Mn |
| Sep 30, 2022 | -3.42 Mn |
| Jun 30, 2022 | -3.02 Mn |
| Mar 31, 2022 | -2.51 Mn |
| Dec 31, 2021 | -3.30 Mn |
| Sep 30, 2021 | -7.70 Mn |